In conclusion, our study demonstrates that YY001, an EP4 antagonist, can reshape the tumor microenvironment in gastric cancer and reactivate the body's immune response (Fig. 8), leading to anti-tumor effects. This evidence concerns the gene PTGER4 and gastric cancer.